- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07282444
Une nouvelle manière de partager les plans de radiothérapie entre médecins, essai CORRECT (CORRECT)
Collaboration en Oncologie entre Radiologues et Radio-oncologues pour l'Évaluation des Cibles Contournées (CORRECT)
This clinical trial tests a new way to share radiation therapy plans using the Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) workflow to improve communication and collaboration between radiation oncologists (ROs) and radiologists when determining cancer targets for radiation treatment. Systemic barriers limit critical communication between radiation oncologists and radiologists and can lead to both under and overdosing of radiation therapy (RT) tumor targets and failures to properly interpret post-treatment imaging. The limited formal diagnostic radiology training of many providers can make differentiating normal from disease imaging findings during target determination difficult, especially in complex disease sites like the lung, head, and neck. Inaccurate target determination may result in cancer return, excess toxicity, or both. Likewise, radiologists who cannot access prior RT plans may mistake expected RT changes for recurrent cancer or overlook true progression. The CORRECT workflow was developed by ROs and radiologists to address RO-radiology communication barriers by facilitating sharing of comprehensive RT target contours during RT planning. The CORRECT workflow begins with the normal process of RO target contouring. Computed tomography (CT) images are then fused with RT targets and pushed to a pre-designated Picture Archiving and Communications System (PACS) software folder accessible by the radiology department. The radiologist can then review the fused images at their chosen time and annotate images to indicate potential deviations (e.g., not avoiding normal tissue or not including all tumor). The RO reviews the annotated images and decides if any changes to treatment targets are needed for the final treatment plan. Through this independent, asynchronous review of high-quality images, CORRECT overcomes many of the limitations of existing communication methods between RO-radiologist, fostering a more collaborative, efficient, and precise approach to cancer treatment planning.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
PRIMARY OBJECTIVE:
To determine the feasibility of the CORRECT workflow, defined as the return of radiology feedback via CORRECT within 2 business days from receipt of initial RT targets.
SECONDARY OBJECTIVES:
I. To further assess the feasibility of the CORRECT workflow as measured by 1) time (in business days) required to install the information technology (IT) application at each practice, 2) the number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance, 3) percentage of approached patients who declined consent.
II. To assess ROs and radiologists' perceptions of acceptability, appropriateness and feasibility of the CORRECT workflow using the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and Feasibility of Intervention Measure (FIM), along with the acceptability of CORRECT workflow training.
III. To identify facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial using a qualitative interview.
OUTLINE:
ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Karen Craver
- Numéro de téléphone: 336-716-0891
- E-mail: NCORP@wfusm.edu
Lieux d'étude
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest NCORP Research Base
-
Contact:
- Kathryn E Weaver, PhD
- Numéro de téléphone: 336-716-0891
- E-mail: kathryn.weaver@wfusm.edu
-
Contact:
- Karen T Craver, MT
- Numéro de téléphone: 3367160891
- E-mail: karen.craver@advocatehealth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- PRACTICE: Must provide radiation therapy for ≥ 3 patients per month with lung cancer or head & neck cancer
- PRACTICE: At least one radiation oncologist and one radiologist (in house, contracted, etc.) at the practice willing to participate, but may have multiple participants at the practice
- PRACTICE: Radiation oncologist/radiologist team must use Picture Archiving and Communication System (PACS) software at this practice
- RADIATION ONCOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
- RADIATION ONCOLOGIST (NON-PATIENT): Must treat lung and/or head & neck cancer patients with curative intent radiation therapy
- RADIATION ONCOLOGIST (NON-PATIENT): Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
- RADIATION ONCOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
- RADIOLOGIST (NON-PATIENT): Must have been in independent practice (i.e., performing duties without preceptor oversight) for a minimum of six months
- RADIOLOGIST (NON-PATIENT): Agree to review pre-treatment radiation therapy targets during the course of the study duration (approximately 12 months). Willing and able to participate in 15 minutes of mandatory virtual CORRECT training
- RADIOLOGIST (NON-PATIENT): Willing to participate in a 30-minute interview, if selected at the end of the study
- PATIENT: Must have any stage of clinically diagnosed lung or head & neck (HN) cancer
- PATIENT: Planned treatment with curative intent definitive RT (with or without other treatments). Curative intent RT must be documented in the electronic medical record (EMR) by the treating radiation oncologist
- PATIENT: Must be expected to be treated by a radiation oncologist participating in this study
- PATIENT: Must be 18 years or older
Exclusion Criteria:
- PRACTICE: Participation by the Community Site or Academic Community Site in another National Cancer Institute (NCI) Community Oncology Research Program (NCORP) Cancer Care Delivery Research (CCDR) U34-supported protocol funded in NCI fiscal year 2025 or later. (Note: WF- 2301CD CONNECT is exempt from this policy, as it was funded prior to NCI fiscal year 2025.)
- RADIATION ONCOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
- RADIATION ONCOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
- RADIOLOGIST (NON-PATIENT): Planning to leave their position at this practice within the next 12 months
- RADIOLOGIST (NON-PATIENT): Providing service on a temporary basis (i.e., locum tenens providers)
- PATIENT: Unable to understand English or Spanish
- PATIENT: Early glottic larynx cancer planned for definitive RT alone
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Health Services Research (CORRECT workflow)
ROs and radiologists receive training on the use of the CORRECT workflow and practice with test cases. ROs and radiologists then use the CORRECT workflow with patient cases for 12 months. |
Ancillary studies Ancillary studies Ancillary studies Receive training and practice cases on CORRECT workflow Use CORRECT workflow |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The return of radiology feedback via Collaborative Oncology between Radiologists and Radiation oncologists for the Evaluation of Contoured Targets (CORRECT) (feasibility)
Délai: Within 2 business days from receipt of initial radiation therapy (RT) targets
|
If > 50% of patients have target feedback returned to the radiation oncologist within 2 business days, this workflow will be considered feasible in community practice. |
Within 2 business days from receipt of initial radiation therapy (RT) targets
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time (in business days) required to install the information technology (IT) application
Délai: During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.
|
Will be assessed at each practice as tracked on the CORRECT IT data form |
During study start-up prior to the enrollment of first patient case; up to 60 days after CIRB approval at the practice.
|
|
The number and proportion of cases per practice with reports of technical issues requiring centralized IT or CORRECT study team assistance
Délai: During RT planning for each patient; over the 9 months of of patient accrual
|
Will be assessed at each practice as tracked on the CORRECT IT data form. |
During RT planning for each patient; over the 9 months of of patient accrual
|
|
Percentage of approached patients who declined consent
Délai: During screening and enrollment over the 9 months of patient accrual
|
Will be assessed at each practice as tracked on the Patient Refusal form. |
During screening and enrollment over the 9 months of patient accrual
|
|
Acceptability of the CORRECT workflow.
Délai: Up to 2 months after patient enrollment has concluded
|
Will be assessed using the Acceptability of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score. |
Up to 2 months after patient enrollment has concluded
|
|
Appropriateness of the CORRECT workflow
Délai: Up to 2 months after patient enrollment has concluded
|
Will be assessed using the Intervention Appropriateness Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score. |
Up to 2 months after patient enrollment has concluded
|
|
Feasibility of the CORRECT workflow
Délai: Up to 2 months after patient enrollment has concluded
|
Will be assessed using the Feasibility of Intervention Measure. Will be collected on the post-study radiation oncologist/radiologist survey. Scale has four items measured on a Likert scale from 1 (completely disagree) to 5 (completely agree). The four items are averaged to obtain a final score. |
Up to 2 months after patient enrollment has concluded
|
|
Facilitators and barriers to radiation oncology-radiology standard of care collaboration, CORRECT workflow implementation, and participation in the future trial
Délai: Up to 2 months after patient enrollment has concluded
|
Will be identified using qualitative interviews using the radiation oncologist/radiologist interview guide. |
Up to 2 months after patient enrollment has concluded
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chaise d'étude: Kathryn Weaver, PhD, Wake Forest University Health Sciences
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Maladies pulmonaires
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Qualité des soins de santé, accès et évaluation
- Techniques d'investigation
- Méthodes épidémiologiques
- Collecte de données
- Mécanismes d'évaluation des soins de santé
- Qualité des soins de santé
- Santé publique
- Environnement et santé publique
- Facteurs socioéconomiques
- Caractéristiques de la population
- Entretiens comme sujet
- Statut éducatif
Autres numéros d'identification d'étude
- IRB00141160
- P30CA012197 (Subvention/contrat des NIH des États-Unis)
- UG1CA189824 (Subvention/contrat des NIH des États-Unis)
- U34CA297499 (Subvention/contrat des NIH des États-Unis)
- NCI - 2025-07036 (Autre identifiant: NCI Trial Identifier)
- WF-2402CD (Autre identifiant: CTEP Identifier)
- WF-2402CD (Autre identifiant: Lead Organization Identifier)
- WF-2402CD (Autre identifiant: DCP Identifier)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.
Délai de partage IPD
6 months after publication for a 2 year duration
Critères d'accès au partage IPD
upon request to NCORP@wfusm.edu
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .